Phase 3 treatment trial in recently infected asymptomatic patients showed regen-cov™ (casirivimab with imdevimab) significantly reduced progression to symptomatic covid-19

Tarrytown, n.y., april 12, 2021 /prnewswire/ -- second phase 3 trial undertaken in collaboration with niaid to announce results today, both using subcutaneous administration of regen-cov in asymptomatic individuals without prior covid-19 infection regeneron pharmaceuticals, inc. (nasdaq: regn) today announced positive data from a phase 3 trial (2069b) of recently infected asymptomatic covid-19 patients, evaluating regen-cov™ (casirivimab with imdevimab) 1,200 mg administered via subcutaneous (sc) administration.
REGN Ratings Summary
REGN Quant Ranking